B+
Bull case
18%
Probability
Target price
$6.25
+78.6% vs current
PRLD
Prelude TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
57%
Probability
Target price
$3.50
0.0% vs current
B-
Bear case
25%
Probability
Target price
$1.50
-57.1% vs current
AI sentiment snapshot
Latest data as of 2026-06-03
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+75.3
Score
AI commentary
This remains a cautious monitoring setup rather than a high-conviction bullish thesis. Primary-source filings show real operational progress and a much longer cash runway, but the business is still early-stage and the market has not granted a durable rerating. The post-earnings note was constructive on estimates and target price, yet the immediate reaction was weak and coverage is thin, so the setup still depends on actual clinical proof rather than financial de-risking.
RankAlpha Sentiment Codex - 2026-06-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-12eventPRT12396 Phase 1 enrollment is the next concrete execution checkMedium impact
The company reported initiation and enrollment of the Phase 1 study for PRT12396, its mutant-selective JAK2V617F inhibitor, in PV and MF [#SEC-8K-2026-05-12]. A clean first-human-study start supports the strategic reset, while any delay or tolerability issue would quickly pressure sentiment.
2026-05-12catalystMay financing extends runway but keeps dilution overhangMedium impact
Prelude said current cash runway is expected into Q2 2028, driven by the previously announced underwritten offering with $90 million gross proceeds [#SEC-8K-2026-05-12]. That removes near-term solvency pressure, but the equity still needs clinical proof before the market rewards the added cash.
2027-12-31catalyst2027 data catalysts from both pipeline programsHigh impact
Prelude said it remains on track to advance PRT12396 and PRT13722 into clinical development and to reach potential key data catalysts from both modalities in 2027 [#10-K-2026-03-10]. If both programs stay on schedule, the market may begin to value PRLD as a multi-shot clinical story rather than a single-program microcap biotech.
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology